On February 25, 2026, Palvella Therapeutics, Inc. completed a significant funding round by entering into an underwriting agreement for the sale of its common stock. The company agreed to issue 1,600,000 shares at a public price of $125.00 per share. This funding will support the company's continued development of its innovative therapies
Who to call at Palvella Therapeutics, and when
A new round usually means Palvella Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Palvella Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Palvella Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Palvella Therapeutics
Location
125 STRAFFORD AVENUE
Wayne, Pennsylvania, United States
About
Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Palvella Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
WayneBiotechnology